本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的，不可用于人类或动物的临床诊断或者治疗，非药用，非食用。
雷莫芦单抗
英文名：Ramucirumab
Cas号：947687-13-0
Cas号：947687-13-0
检测信息查询
| 别 名 | |
| Cas号 | 947687-13-0 |
| M D L | |
| 分子式 | |
| 分子量 | |
| 产品参数 | Description
Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors[1]. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D[2]. IC50 & Target[1][2] VEGFR-2 |
| 性状 | Ramucirumab 是人 VEGFR-2 拮抗剂，可用于治疗实体瘤。Ramucirumab 是一种人源化单克隆抗体，可与 VEGFR-2 结合，阻止 VEGFR 配体 VEGF-A，VEGF-C 和 VEGF-D 结合 |
| 贮存 | Storage Please store the product under the recommended conditions in the Certificate of Analysis. References [1]. Fala L. Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer. Am Health Drug Benefits. 2015 Mar;8(Spec Feature):49-53. [2]. Oholendt AL, et al. Ramucirumab: A New Therapy for Advanced Gastric Cancer. J Adv Pract Oncol. 2015 Jan-Feb;6(1):71-5. |
- 托珠单抗 375823-41-9
- 伊匹单抗 477202-00-9
- 维多珠单抗 943609-66-3
- 优特克诺 815610-63-0
- 雷莫芦单抗 947687-13-0
- Human IgG1 Control
- Abatacept 332348-12-6
- Obinutuzumab
- Reslizumab 241473-69-8
沪公网安备 31012002003054号